On August 19, the closing ceremony of the 14th China Innovation and Entrepreneurship Competition (Liaoning Division) was successfully held in Dalian City. Liaoning Unicornshell Pharmaceutical Technology Co., Ltd. won the first prize in the start-up enterprise group of the biomedical industry competition for its innovative strength in the field of plant-based pharmaceutical excipients, and was awarded a certificate and trophy. This honor highlights Unicornshell's technical strength in intelligent manufacturing and green new material applications.
Overview of This Year's Competition
This year's competition, themed “Gathering Through Innovation, Embracing the Future Together,” was organized by the Liaoning Provincial Department of Science and Technology and hosted by the Provincial Science and Technology Innovation Service Center. It attracted numerous innovative enterprises from across the province, providing them with a platform to showcase their innovations and access policy and capital support. The competition serves as an important barometer of innovation and entrepreneurship in Liaoning Province.
Congratulations on Your Success
This award reflects Unicornshell's strengths in R&D capabilities, technological achievements, and corporate management. Headquartered in Shanghai, Unicornshell specializes in the research, development, production, and sales of plant-based pharmaceutical excipients and innovative traditional Chinese medicine formulations, aiming to become a leader in the intelligent manufacturing of plant-based capsules. The company is committed to “promoting medication safety and safeguarding human health,” driving the deep integration of intelligent manufacturing and new materials to support the upgrading of the pharmaceutical industry and the modernization of traditional Chinese medicine.
Its core products include hydroxypropyl methylcellulose capsules and hydroxypropyl starch capsules, which possess multiple strategic attributes including biopharmaceuticals, intelligent manufacturing, new materials, and import substitution, aligning with national industrial policies and the development needs of rural revitalization. Plant-based capsules represent an important future direction for pharmaceutical excipients, aligning with the national “14th Five-Year Plan” for high-quality pharmaceutical development and the encouraging policies outlined in the “Guidance Catalog for Industrial Structure Adjustment (2019 Edition).” They fundamentally address the safety concerns associated with traditional gelatin capsules, driving the industry toward high-quality development.
Future Outlook · Global Perspective
Unicornshell will continue to adhere to the dual-drive strategy of “technological innovation + market expansion,” deepen industry-academia-research collaboration, strengthen intellectual property protection, and build an internationally leading plant-based capsule industrial system.
In the future, the company will continue to use foreign trade channels as a breakthrough point, focusing on expanding into Southeast Asia, Central Asia, and European markets to form diversified growth pathways; closely follow domestic policies to seize new market opportunities; and collaborate deeply with pharmaceutical companies to promote the application of plant-based capsules in innovative drugs. Through global expansion and industrial synergy, Unicornshell aims to become a leader in the plant-based capsule industry and contribute “Chinese momentum” to the high-quality development of the national biopharmaceutical industry.
Innovation-Driven, Strength-Enhanced
Committed to innovation, living up to expectations: Unicornshell secured the championship title in the industry competition of the Liaoning Province region with outstanding performance, with a promising future ahead!
